Selected research
Industry Growth & Trends
Global Live Vaccines Industry Growth and Trends Forecast to 2032
Market perspective
The global Live Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Live Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Live Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Live Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Live Vaccines include Astellas Pharma, Emergent BioSolutions, AstraZeneca, GlaxoSmithKline, Pfizer, Merck and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Live Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Live Vaccines market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Live Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Live Vaccines.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Live Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Live Vaccines Market by Company
Astellas Pharma
Emergent BioSolutions
AstraZeneca
GlaxoSmithKline
Pfizer
Merck
Novartis
Live Vaccines Segment by Type
Monovalent Live Vaccines
Multivalent Live Vaccines
Live Vaccines Segment by Application
Adults
Children
Live Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Live Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Live Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monovalent Live Vaccines
- Multivalent Live Vaccines
Applications
- Adults
- Children
Companies covered
- Astellas Pharma
- Emergent BioSolutions
- AstraZeneca
- GlaxoSmithKline
- Pfizer
- Merck
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Live Vaccines Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Live Vaccines Sales Estimates and Forecasts (2021-2032)
- 1.3 Live Vaccines Market by Type
- 1.3.1 Monovalent Live Vaccines
- 1.3.2 Multivalent Live Vaccines
- 1.4 Global Live Vaccines Market Size by Type
- 1.4.1 Global Live Vaccines Market Size Overview by Type (2021-2032)
- 1.4.2 Global Live Vaccines Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Live Vaccines Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Live Vaccines Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Live Vaccines Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Live Vaccines Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Live Vaccines Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Live Vaccines Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Live Vaccines Industry Trends
- 2.2 Live Vaccines Industry Drivers
- 2.3 Live Vaccines Industry Opportunities and Challenges
- 2.4 Live Vaccines Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Live Vaccines Revenue (2021-2026)
- 3.2 Global Top Players by Live Vaccines Sales (2021-2026)
- 3.3 Global Top Players by Live Vaccines Price (2021-2026)
- 3.4 Global Live Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Live Vaccines Major Company Production Sites & Headquarters
- 3.6 Global Live Vaccines Company, Product Type & Application
- 3.7 Global Live Vaccines Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Live Vaccines Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Live Vaccines Players Market Share by Revenue in 2025
- 3.8.3 2025 Live Vaccines Tier 1, Tier 2, and Tier 3
4 Live Vaccines Regional Status and Outlook
- 4.1 Global Live Vaccines Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Live Vaccines Historic Market Size by Region
- 4.2.1 Global Live Vaccines Sales in Volume by Region (2021-2026)
- 4.2.2 Global Live Vaccines Sales in Value by Region (2021-2026)
- 4.2.3 Global Live Vaccines Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Live Vaccines Forecasted Market Size by Region
- 4.3.1 Global Live Vaccines Sales in Volume by Region (2027-2032)
- 4.3.2 Global Live Vaccines Sales in Value by Region (2027-2032)
- 4.3.3 Global Live Vaccines Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Live Vaccines by Application
- 5.1 Live Vaccines Market by Application
- 5.1.1 Adults
- 5.1.2 Children
- 5.2 Global Live Vaccines Market Size by Application
- 5.2.1 Global Live Vaccines Market Size Overview by Application (2021-2032)
- 5.2.2 Global Live Vaccines Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Live Vaccines Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Live Vaccines Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Live Vaccines Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Live Vaccines Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Live Vaccines Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Live Vaccines Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Astellas Pharma
- 6.1.1 Astellas Pharma Company Information
- 6.1.2 Astellas Pharma Business Overview
- 6.1.3 Astellas Pharma Live Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Astellas Pharma Live Vaccines Product Portfolio
- 6.1.5 Astellas Pharma Recent Developments
- 6.2 Emergent BioSolutions
- 6.2.1 Emergent BioSolutions Company Information
- 6.2.2 Emergent BioSolutions Business Overview
- 6.2.3 Emergent BioSolutions Live Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Emergent BioSolutions Live Vaccines Product Portfolio
- 6.2.5 Emergent BioSolutions Recent Developments
- 6.3 AstraZeneca
- 6.3.1 AstraZeneca Company Information
- 6.3.2 AstraZeneca Business Overview
- 6.3.3 AstraZeneca Live Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 AstraZeneca Live Vaccines Product Portfolio
- 6.3.5 AstraZeneca Recent Developments
- 6.4 GlaxoSmithKline
- 6.4.1 GlaxoSmithKline Company Information
- 6.4.2 GlaxoSmithKline Business Overview
- 6.4.3 GlaxoSmithKline Live Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 GlaxoSmithKline Live Vaccines Product Portfolio
- 6.4.5 GlaxoSmithKline Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Live Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Pfizer Live Vaccines Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Merck
- 6.6.1 Merck Company Information
- 6.6.2 Merck Business Overview
- 6.6.3 Merck Live Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Merck Live Vaccines Product Portfolio
- 6.6.5 Merck Recent Developments
- 6.7 Novartis
- 6.7.1 Novartis Company Information
- 6.7.2 Novartis Business Overview
- 6.7.3 Novartis Live Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Novartis Live Vaccines Product Portfolio
- 6.7.5 Novartis Recent Developments
7 North America by Country
- 7.1 North America Live Vaccines Sales by Country
- 7.1.1 North America Live Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Live Vaccines Sales by Country (2021-2026)
- 7.1.3 North America Live Vaccines Sales Forecast by Country (2027-2032)
- 7.2 North America Live Vaccines Market Size by Country
- 7.2.1 North America Live Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Live Vaccines Market Size by Country (2021-2026)
- 7.2.3 North America Live Vaccines Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Live Vaccines Sales by Country
- 8.1.1 Europe Live Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Live Vaccines Sales by Country (2021-2026)
- 8.1.3 Europe Live Vaccines Sales Forecast by Country (2027-2032)
- 8.2 Europe Live Vaccines Market Size by Country
- 8.2.1 Europe Live Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Live Vaccines Market Size by Country (2021-2026)
- 8.2.3 Europe Live Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Live Vaccines Sales by Country
- 9.1.1 Asia-Pacific Live Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Live Vaccines Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Live Vaccines Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Live Vaccines Market Size by Country
- 9.2.1 Asia-Pacific Live Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Live Vaccines Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Live Vaccines Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Live Vaccines Sales by Country
- 10.1.1 South America Live Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Live Vaccines Sales by Country (2021-2026)
- 10.1.3 South America Live Vaccines Sales Forecast by Country (2027-2032)
- 10.2 South America Live Vaccines Market Size by Country
- 10.2.1 South America Live Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Live Vaccines Market Size by Country (2021-2026)
- 10.2.3 South America Live Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Live Vaccines Sales by Country
- 11.1.1 Middle East and Africa Live Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Live Vaccines Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Live Vaccines Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Live Vaccines Market Size by Country
- 11.2.1 Middle East and Africa Live Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Live Vaccines Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Live Vaccines Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Live Vaccines Value Chain Analysis
- 12.1.1 Live Vaccines Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Live Vaccines Production Mode & Process
- 12.2 Live Vaccines Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Live Vaccines Distributors
- 12.2.3 Live Vaccines Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst